Study Protocol: LIAM Mc Trial (Linking In with Advice and supports for Men impacted by Metastatic cancer)

Study Design

“The LIAM Mc Trial – Linking In with Advice and supports for Men impacted by Metastatic cancer” is a single arm feasibility study of introducing a men’s cancer survivorship intervention programme alongside routine follow-up care in patients with advanced genitourinary malignancies. The programme entails physiotherapy, dietetics, nursing and psychosocial components, with signposting to already-available supportive care services at regular intervals and is aimed at better engaging with and supporting men in Ireland post-cancer treatment. Patients, in groups of 6, are provided with personalised care plans with supervised exercise and education sessions. There are two phases: a Pilot Phase involving the first group of 6 participants, followed by an Expansion Phase.

As an initial part of the study planning, a scoping review of 30 studies (5) was carried out to describe the effect of supportive care interventions for men with any genitourinary cancer and highlighted the lack of studies including men with non-prostate genitourinary cancers. This review informed the Pilot Phase involving 6 men with advanced prostate cancer. The initial number of participants per intervention group was determined by the Steering Group, based on the availability of the necessary exercise and measurement equipment, and with a view to promoting personalised care plans and to ensure both the safety and quality of the intervention.

The study incorporates an embedded mixed-method process evaluation informed by Medical Research Council guidance (12). This realist process evaluation addresses the context of the pilot study and factors that influence the outcomes of the study i.e. “what works, for whom, under what circumstances” (13, 14). The process evaluation will use the LOGIC model to systematically and visually present, map and share our understanding of the relationships among the resources used to underpin the intervention, the activities planned (intervention inputs, processes, actions) and outputs, outcomes, and impact (14). The key evaluation will occur at the end of the core trial activity which is a 12-week intervention programme (see Figure 1 SPIRIT Schedule and Figure 2 The Liam Mc Trial Flow Diagram)

• Download figure
• Open in new tab

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 1.

SPIRIT Schedule

• Download figure
• Open in new tab

Figure 2.

The Liam Mc Flow Diagram

Research Ethics

This study will be conducted in accordance with the Declaration of Helsinki, the applicable sections of ICH E6 Good Clinical Practices (15) and the terms of approval of the responsible Clinical Research Ethics Committee of the University’s Teaching Hospital. Full ethical approval for the trial was granted by the Clinical Research Ethics Committee in November 2022 (ECM 4 (v) 01/11/2022). All subsequent amendments to the protocol which impacted or may impact the study’s conduct have been or will be submitted as amendments for approval to the ethics committee. The study is registered with ClinicalTrials.gov with a trial registration number of NCT05946993, Cancer Trials Ireland CTRIAL-IE 23-18 and UCC #22052. The manuscript is reported using the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist for a clinical trial protocol (16) (Additional File 1)

Study participants

Men aged 18 years and above, with advanced or metastatic genitourinary cancer (including prostate, kidney, urothelial tract, testicular or penile cancer), are eligible for inclusion in the study provided they are currently stable on maintenance systemic therapy, i.e. they do not have ongoing adverse events which would impact their participation in the programme at the time of commencing the 12-week intervention, or have recently completed a systemic therapy and are planned for active surveillance (i.e., no active systemic therapies at present) as part of their care for their genitourinary cancer treatment. Of note, men with resected disease (adjuvant setting) are eligible if they have commenced or completed adjuvant systemic therapy within the past 12 months and have recovered from adverse events from these treatments that would impact their participation at the time of commencing the 12-week programme.

Detailed inclusion and exclusion criteria are outlined in Table 1.

Recruitment and screening

Participants will be recruited across a university hospital group comprising three participating hospitals -Cork University Hospital, the Mercy University Hospital and the Bon Secours Hospital - within a health service region in the Republic of Ireland. A target sample of 72 participants meeting the predefined inclusion criteria will be recruited. Potential participants will be screened by the oncology clinical care team or research team to determine eligibility and all those who meet the inclusion criteria will be invited to participate. Verbal and written information regarding the study will be provided, with ample time for review before written informed consent is completed at the initial assessment. All study participants who provide written informed consent will be enrolled in the study. The Castor Electronic Data Capture (EDC) platform (https://www.castoredc.com/) will be used to collect and store the study data. Study participants will be facilitated with access to the electronic patient-reported outcome (ePRO) measurement system via Castor EDC.

Recruitment take place over a 24-month period. The study duration for each participant will involve a 12-week intervention and a follow up survey at 6 months. Strategies being taken to reach the target sample size of 72 include readily available study brochures and contact details, the use of social media and print media, and education of oncology staff in the participating hospitals about the study.

Following consent and enrolment, participants will be assigned a unique study identifier and access to the ePRO measurement system. A 6-week screening period, to assess eligibility and capture baseline assessments prior to commencing the 12-week intervention programme, will involve an initial assessment and time for consent. At the initial assessment, baseline assessments will include the following:

1. Baseline questionnaire/needs, burden of disease and quality of life assessment

2. Dietetic Evaluation

3. Physiotherapy Evaluation

Information on the questionnaires, evaluations and consent processes are contained in the trial protocol (Additional File 2).

Intervention

The 12-week intervention programme will involve twice-weekly visits from week 1–12 (1 × 1.5-hour session, 1 × 1-hour session per week). The intervention programme will be conducted in a purposefully designed rehabilitation gymnasium. This allied health professional-led programme includes physiotherapist input twice per week, dietitian input every 2 weeks, specialist nursing input every 2 weeks, medical social worker input and psycho-oncology input, with programme oversight by medical oncologists. An outline of the programme is provided in Figure 3.

• Download figure
• Open in new tab

Figure 3.

Outline of the Programme

The initial assessment visit involves assessing and managing current symptoms and needs per management pathways, referring patients to appropriate specialists, and ensuring future access to the clinic where needed during the study period. The baseline physical and nutritional assessments will be undertaken at this visit. Patients will receive individualised education on exercise, diet and symptom management plans, depending on the outcome of the baseline assessments, or according to clinical judgement. Diet education and personalised nutrition counselling will be performed throughout the study.

A study evaluation will take place, at the evaluation stage of the Pilot Phase, of potential barriers that participants perceive would prelude them in attending face to face. Anticipated barriers include access to travel, a translator, expenses incurred or family/work commitments. It is the intention of the research team to explore all feasible means to address identified barriers for later phase participants. A patient access fund is also available to help reduce barriers to enrolment. If participants cannot attend the scheduled sessions on a given day, then virtual meeting or recording options will be explored so that they can still receive the educational components of the intervention.

Participant flow through the study

Figure 2 depicts an overview of study participants using the Consolidated Standards of Reporting Trials (CONSORT) flow diagram (18). The Pilot Phase 12-week programme of the first 6 men will be completed and analysed prior to commencement of the Expansion Phase from Q3 of year 1 onwards. Patients will participate in the programme for a total of up to 12 months. They will complete surveys during the first 12 weeks of the study (Screening/Baseline and End of Treatment) and then at the 6-month timepoint. A focus group with study participants will take place at the end of the 12-week programme. In addition, participants will be invited to Public and Patient Involvement (PPI) engagement meetings quarterly after completion of the 12-week intervention programme and for the duration of the study period (2 years).

Follow up for routine medical oncology care and surveillance will take place as normal, through the medical oncology clinics, see Figure 3. Study-specific follow up will take place 6 months after completion of the 12-week intervention programme.

If the participant decides to cease involvement, the research nurse will liaise with the participant to discuss their reasons for not continuing in the study. Reasons for declining participation in the study or discontinuation during the study period will be collected as part of the feasibility outcomes. Specific reasons for withdrawal of interest will be recorded in the relevant case report form.

Study objectives

The primary objective of the study is to demonstrate the feasibility of introducing a men’s cancer survivorship intervention programme alongside routine follow up care in patients with advanced genitourinary malignancies. Secondary objectives include evaluation of the impact of the intervention programme on quality of life, cancer-related fatigue, body weight, lean tissue mass, fat mass, muscle strength and nutritional risk, dietary intake and quality, self-care agency, resource utilisation of signposted services and economic impact of a men’s cancer survivorship intervention programme.

Study Outcomes/Measures

Data collection will occur at three designated timepoints; Initial assessment, after completing the 12-week intervention and at 6 months post intervention. Completion of a process evaluation as part of the feasibility testing and secondary outcome measurement will also occur after all participants have completed the 12-week intervention.

Adverse events

Adverse events (AEs) of interest (those deemed potentially related to the intervention) will be recorded and assessed for relationship to the intervention programme throughout the study period. Adverse Events will be documented and graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Patient reporting of an AE to a health care professional will trigger recording of the AE.

Serious Adverse Events (SAEs), defined for the purposes of this study as CTCAE v5.0 grade ≥3 adverse events of any kind, or those grade <3 but deemed by an investigator to be serious, will be reported to the LIAM Mc Steering Group for review at the following meeting. SAEs of grade ≥4 will trigger a pause in the study for safety reasons until the SAE has been formally assessed and a decision made to either proceed with or terminate the study.

The research team do not anticipate any adverse events associated with completion of the patient-reported outcomes. Patients will have the option of skipping questions they do not wish to answer. In the event that study participation does result in any event that has significant negative consequences for the subject, this will be recorded by an investigator in the EDC (Electronic Data Capture) and will be reported to the Sponsor and Ethics committee.

Data management and analysis

The study’s protocol is accompanied by a Data Management Plan. For confidentiality purposes, a study-specific ID code will serve as a unique identifier on the case-report forms for all study participants. The codes will be stored separately from the main study database and other study documentation. This unique ID subject code will be linked to the participant’s identifying information by a participant identity list maintained by the study’s Principal Investigator in a secure location at the clinical site of the study. The list of ID codes will not be forwarded to any third party. The purpose of the ID code is to facilitate subsequent follow-up of participants in the event of requiring symptom management intervention.

An on-site Trial Master Folder (TMF) containing confidential data in the form of hard copies of regulatory documents and participant-related information will be kept in a locked cabinet in a locked room, accessible only by the study’s research team members. An electronic TMF containing confidential regulatory documents, participant-related information, and patient public interactions will be maintained in a dedicated database in a secure location. This confidential electronic data will be stored and backed-up monthly in encrypted folders on a health service laptop, and in the validated web-based nutritional analysis software tool, Nutritics (https://www.nutrics.com/app/). Access to the database will be controlled at the level of the individual with specific roles assigned, with concomitant access rights (e.g. data manager, auditor). At the end of the study, all anonymised data will be available to the study’s principal statistician, while researchers nominated by the Principal Investigator will also be able to access the final trial dataset.

The study’s primary data catalogue, encompassing primary participant data (case-report forms) and participant responses to electronic surveys, will be collected and managed using the Castor EDC platform. This platform meets national and international guidelines with respect to data privacy and data protection standards. Once data entry is finalised, study data will be assessed for incompatible, discrepant, or clinically implausible values. Outlying values for all distributions, in isolation and over time, will be identified. Any concerning data will be reconciled against the original source data. Following the completion of cleaning, the database will be locked.

Sample size

There is no gold standard for sample size calculation in feasibility studies (23). Given that the goal of a feasibility study is to identify problems that would impede the conduct of a larger, efficacy study, we have set the sample size at 59 based on advice from Viechtbauer et al. (24), which is aimed at being able to detect failures in study processes that would occur just 5% of the time (with 95% confidence). A target sample size of 72 allows for sample attrition (around 20% attrition rate) from men withdrawing due to illness, or waning commitment/interest. Therefore, a target sample size of 72, based on enrolling 12 groups of 6 men in Sequential Cohorts/Parallel Sampling Groups over the 2-year period, will be used and will inform feasibility of the programme.

Statistical Considerations / Analyses

Quantitative data will be analysed using R Project for Statistical Computing and the RStudio IDE and presented using percentages, means (SD), modes, and medians with an interquartile range (IQR) as appropriate.

Qualitative data will be digitally recorded, verbatim transcripts will be prepared from the sound files, and transcripts will be checked for accuracy against the sound files and anonymised. Thematic content analysis will be used to code data in transcripts that is relevant to the process evaluation (25). NVivo software will be used to assist with the analysis. One researcher trained in qualitative research methods will analyse the qualitative data allowing for fuller immersion and to obtain an overall sense of the data. To enhance trustworthiness, this process will be checked for accuracy by a minimum of two researchers. Initial open coding will be organised into higher level coding, and thematic interpretations. Data analysis will be iterative such that early interviews can inform questions in later interviews. Quantitative and qualitative data will be integrated to provide an overall perspective on the process of implementing the intervention/study. We will do that by describing what was delivered in the intervention, what process effects were observed, then identify explanatory ‘Context + Mechanism → Process effect’ alignments that explain how the intervention, and the study more broadly, was perceived by participants, if/why this varied, and how these perceptions affected receptivity to the intervention.

Once data entry is finalised, study data will be assessed for incompatible, discrepant or clinically implausible values. Outlying values for all distributions, in isolation and over time, will be identified. Any concerning data will be reconciled against original source data. Following completion of cleaning the database will be locked.

The study sample will be described in detail. Continuous variables will be described by their means and SDs, medians and IQRs, and their range; while categorical variables will be described by their counts and percentages in each category.

Feasibility outcomes will be similarly described. These include the number of enrolled patients who complete the initial assessment and follow-up assessments, and the number of patients who partake in all planned activities versus less than all; the number of patients that require medical review and the timeframe to medical review; changes in muscle strength and mass from initial assessment to end of programme assessments; changes in dietetic assessments from initial assessment to end of programme assessments; changes in QOL outcome measures from initial assessment to end of programme assessments; the number of patients enrolled in the programme; extra HCP time required and resources required for the intervention; and reasons for not completing the programme will be collected through Drop Out Forms and with qualitative discussions with HCPs involved in the programme.

Missing data will be evaluated, and based on what we observe, dealt with in whatever manner we find appropriate based on current best practices. All analyses will be conducted using the R Project for Statistical Computing and the RStudio IDE. All trial reporting will be done following CONSORT and the CONSORT addendum for pilot/feasibility trials (26).

Data monitoring

The university as the study sponsor is the Data Controller responsible for the study. Castor EDC provides for a full audit trail of user actions to be recorded, and data check procedures for Castor EDC will be conducted every 3 months from the start of the recruitment process by the study team. Biannual monitoring reports will be provided to the study’s Sponsor Office, and a Clinical Trial Audit will be provided by the study’s Clinical Research Facility as required from the Sponsor Office. The study team will provide annual reports to the study’s funders as expressed in the funding agreements. Based on the nonmedical intervention and low-risk nature of participation in the study, a Data Monitoring Committee was deemed unnecessary.

Dissemination

In consultation with the study funders, it is planned to disseminate the key findings of the feasibility trial after the end of the study whereby anonymised individual participant data sets will be shared in the form of results within peer-reviewed publications, academic conferences, workshops, and seminars. Planned public and patient dissemination outputs include public blogs, media, and outreach engagement events, including press articles and seminars. The protocol is published on the ClinicalTrials. gov website, with trial registration number NCT05946993. Post-study shared outputs including the study protocol, data dictionary, and analysis scripts will be available via the Open Science Framework.

Public and Patient involvement (PPI)

The study team members are collaborating with PPI representatives in the design, development, implementation, analysis, and dissemination of the study. The PPI representatives include patient advocates who have had genitourinary or other cancers and represent the patient and public voice at our research meetings. PPI representatives are included in the trial steering group and will be involved in the design, conduct, analysis and dissemination of the study.